{"id":"NCT03138512","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney","officialTitle":"A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-07","primaryCompletion":"2023-09-28","completion":"2024-02-01","firstPosted":"2017-05-03","resultsPosted":"2024-12-18","lastUpdate":"2024-12-18"},"enrollment":1641,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Renal Cell"],"interventions":[{"type":"BIOLOGICAL","name":"nivolumab","otherNames":["Opdivo"]},{"type":"BIOLOGICAL","name":"ipilimumab","otherNames":["Yervoy"]},{"type":"DRUG","name":"nivolumab placebo","otherNames":[]},{"type":"DRUG","name":"ipilimumab placebo","otherNames":[]}],"arms":[{"label":"Part A, Arm A: nivolumab + ipilimumab","type":"EXPERIMENTAL"},{"label":"Part A, Arm B: nivolumab placebo + ipilimumab placebo","type":"PLACEBO_COMPARATOR"},{"label":"Part B, Arm A: nivolumab + ipilimumab","type":"EXPERIMENTAL"},{"label":"Part B, Arm B: nivolumab placebo + ipilimumab placebo","type":"PLACEBO_COMPARATOR"},{"label":"Part B, Arm C: nivolumab + ipilimumab placebo","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have experienced partial or entire removal of a kidney.","primaryOutcome":{"measure":"Disease-Free Survival (DFS) by BICR - Treatment Part A and B","timeFrame":"From randomization to development of local disease recurrence, distance metastasis, or death, whichever came first (up to approximately 72 months)","effectByArm":[{"arm":"Treatment Part A: Nivo + Ipi","deltaMin":null,"sd":null},{"arm":"Treatment Part A: Placebo","deltaMin":null,"sd":null},{"arm":"Treatment Part B: Placebo","deltaMin":null,"sd":null},{"arm":"Treatment Part B: Nivo","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6676"},{"comp":"OG001 vs OG004","p":"0.6556"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":200,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","France","Germany","Italy","Japan","Mexico","Netherlands","Poland","Romania","Russia","Singapore","Spain","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["39303200","36774933","33526329"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","http://www.BMSStudyConnect.com"]},"adverseEventsSummary":{"seriousAny":{"events":196,"n":608},"commonTop":["Fatigue","Pruritus","Diarrhoea","Arthralgia","Headache"]}}